Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010
|
|
- Piers Floyd
- 6 years ago
- Views:
Transcription
1 Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010
2 Content Legal basis What do agencies want? What happens Before During After How do you prepare for it? Industry wishes Conclusions 2
3 Did you say Inspections? Legal basis: Directive 2001/82/EC Art 80 Role of the MAH: to have an appropriate system of Pharmacovigilance (PhV) Role of the Agency & Competent Authorities: to verify, on behalf of the community that the MAH satisfies the requirements as laid down in this Directive and its amendments (Directive 2004/28/EC) MONITORING of COMPLIANCE 3
4 Inspections for what? - 1 Routine inspections Targeted inspections when triggers are reached No specific concerns Specifics concerns Inspections of contractors, licensing partners The agencies want reassurance that the MAH are fulfilling their obligations regarding the PhV requirements laid down by the legislation 4
5 Inspections for what? - 2 To improve post marketing surveillance To help and advise MAHs as necessary If severe breaches are observed repeatedly penalties can be imposed 5
6 What happens? Before the inspection Notice usually given by agency, a few weeks to a few months Information may be requested prior to the inspection SOPs and other procedures Information from DDPS Listing of expedited cases for a given period Calendars of PSURs for compliance with 60 days Third party agreements Product related issues Agreement on logistics, participants, inspection plan 6
7 What happens? During the inspection -1 Opening meeting Introductions Attendees: Inspector(s), PhV staff, QA staff, Management Objectives and the remit of the inspection are agreed Inspection itself, can be a few hours to a few days, ensure that you have a room allocated for the inspectors and staff who know what their role is 7
8 What happens? During the inspection -2 May include Review of PhV cases, documentation and processes: reconstruction of a case, from original data collection, through follow up to reporting PSURs elaboration and risk benefit assessments Review of procedures and their application Interviews with staff involved in all PhV activities, from receptionists to sale reps Review of staff training records, CV, job descriptions 8
9 What happens? During the inspection -3 And Demonstration of the database, looking at maintenance, archiving, security and disaster recovery processes Third party contracts Quality Management system in place Review of archives Process for literature reviews 9
10 What happens? During the inspection -4 Exit Meeting Attendees include the Inspector(s), QA Management, PhV staff and Management To ensure an understanding of findings, not to debate Can provide updates or correct misinformation 10
11 What happens? During the inspection -5 Opportunity to respond to findings as appropriate (some issues may need to be discussed internally prior to making a commitment for follow-up) No written list of findings at this stage but all findings will be described by the inspector Agreement on next steps: the issue of the inspection report 11
12 What happens? After the inspection Inspections draft report issued for comments Final report usually within 4 weeks of inspection Can be a listing of deficiencies classified in critical, major and minor, comments and recommendations, Can be a statement of compliance or non compliance and the issues to be addressed Response from MAH expected usually within 30 days with response plan to address issues If critical findings, may warrant a follow up inspection 12
13 How to prepare for an inspection? -1 Not a last minute activity, should be addressed as part of the Quality Management of PhV Use the guidance provided by legislation, Guidelines, QA teams Quality management system in place SOPs and procedures Training of all concerned staff Regular internal audits of PhV activities and systems should ensure that gaps, issues are identified and addressed Would recommend every 2-3 years Anytime when there is a major change in the PhV system Internal audit prior to a planned inspection Ensure suitable management involvement 13
14 How to prepare for an inspection? - 2 As soon as you are notified Inform your QA group and management and request their presence on the day(s) of inspection Book meeting rooms and assign tasks Ensure the availability of key people (EUQP for example) on the day and adequate resources for dealing with the paperwork Contact inspectors and engage communication 14
15 How to prepare for an inspection? - 3 Other activities May run a refresher to your staff Recommend an internal audit if last one was a while ago Address any easy fix findings Don t make major changes to procedures just prior to the inspection but show that you have identified some issues and your plans to address them Training of concerned staff prior to inspection on do s and don ts on the inspection day On the day: Don t panic! 15
16 Main points of discussions so far -1 Third party contracts Signal detection Congruence of data in house and communicated to/by authorities Training and knowledge of staff involved in PhV activities Periodicity of literature searches Product defect questions Others? 16
17 Main points of discussions so far - 2 Job descriptions Procedures - presence, content, process Validation, conformity of IT systems to EU requirements for electronic submissions Electronic reporting/importing Third country reporting Availability of local and EU QPs for PhV and their back-up Feasibility of urgent 24 hours safety restriction Training: tests for checking training efficacy 17
18 Variety is the spice of life! Areas for clarification: Purpose of inspections Sometimes part of GMP, or GCP inspections or pure PhV inspection Should all inspections be the same? Or tailored to the activity of the site? Diversity of interpretations of requirements between inspectors Fee? No fee? Per site? Per activities? 18
19 Variety is the spice of life! (continued) Inspectors affiliations Human sector vs Veterinary personnel EMA/CVMP mandated inspections vs National inspections GMP personnel Scope of inspection Focus on SOPs Short and sweet inspections (1 to 2 hours) Full PhV inspections (3 days) Based on the activity of the site? h2 19
20 Folie 19 h2 You could also address EMA inspections vs. country based inspections - how are they different? who would be involved? how they are reported? etc harlow_hl;
21 Conclusions Important event for MAH and others inspected Need careful preparation and follow up If well prepared can be quite rewarding as high visibility event at the MAH Don t become complacent afterwards Always an opportunity to learn and improve! Opportunity to gather more support from management Still fairly new area so likely to evolve to a more structured process? 20
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationStakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency
New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,
More informationPROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group
European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors
More informationGxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector
GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector Agenda Introduction to work of the Inspections Sector GxP Inspections within the centralised procedure Regulatory framework
More informationEudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary
More informationPost Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates
Post Marketing PV AUDIT AND INSPECTION HOSTING Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates Agenda Background Preparation Conduct Post Audit & Inspection CAPA Management Audit & Inspection
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationGuidelines for Pharmacovigilance Inspections
PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS
FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationSTANDARD OPERATING PROCEDURE TEAM INSPECTIONS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 031-1 Annex 29 July 2009 STANDARD OPERATING PROCEDURE TEAM INSPECTIONS PIC/S July 2009 Reproduction prohibited for
More informationProcedure management of variations
Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationElectronic exchange of Pharmacovigilance data:
Electronic exchange of Pharmacovigilance data: the industry journey so far and the look ahead to the future Sylvie Meillerais, IFAH-Europe BVL symposium, Berlin 13-14 December 2010 1 Content IFAH-Europe
More informationImplementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories
Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Agenda PSMF PSURs Solicited sources RMPs Inspections Signal detection
More informationAudit of Official Controls in Department of Agriculture, Food and the Marine Approved Poultry (Broiler) Processing (Slaughtering) Establishments
AUDit REPORt Audit of Offi cial Controls in Department of Agriculture, Food and the Marine Approved Poultry (Broiler) Processing (Slaughtering) Establishments Audit REPORT Audit of Official Controls in
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationCMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES
CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationQuality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017
Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 - Pharmacovigilance System - Overall Quality objectives in PV - Quality Management System overview - Quality Management System requirements - Quality
More informationInspections: an academic perspective
Inspections: an academic perspective Patricia Henley Quality and Governance Manager Head, Research Governance & Integrity Office London School of Hygiene & Tropical Medicine Email: patricia.henley@lshtm.ac.uk
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationDJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency
Introduction to EU Regulatory system and GMP Inspection system. The Qualified Person. DJ Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Any views expressed may not necessarily
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 14 July 2008 Doc. Ref. EMEA/INS/GMP/361819/2008 COMMUNITY PROJECT ON THE PRACTICAL IMPLEMENTATION OF THE NEW OBLIGATIONS FOR MANUFACTURING AUTHORISATION HOLDERS
More informationSAFETY CULTURE IN ITALY: THE LEGISLATION, INSPECTIONS, THE PERSPECTIVE OF AN INSPECTOR
SAFETY CULTURE IN ITALY: THE LEGISLATION, INSPECTIONS, THE PERSPECTIVE OF AN INSPECTOR Fabrizio Vazzana ISPRA-Italian National Institute for Environmental Protection and Research AIM: Analyze the dissemination
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationSTRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR Public Section
STRATEGIC PLAN OF THE STATE INSTITUTE FOR DRUG CONTROL FOR 2016-2020 Public Section 1 1. FOREWORD The document SÚKL Strategic Plan for 2016-2020 (hereinafter referred to as the Strategy ) summarises the
More informationThe new Pharmacovigilance legislation and implementation planning
The new Pharmacovigilance legislation and implementation planning Second Stakeholders meeting 17 June 2011 European Medicines Agency, London, UK Presented by: Franck Diafouka Manager, Pharmacovigilance
More informationENCePP Plenary: New Pharmacovigilance legislation
ENCePP Plenary: New Pharmacovigilance legislation 18 November 2010 Peter Arlett Head of Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk 1. New pharmacovigilance legislation:
More informationEMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)
7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures
More informationAgenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)
EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationThe APIC Audit Programme Version 3, August 2010
The APIC Audit Programme Version 3, August 2010 Table of contents 1 General 2. APIC Audit Program 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationGVPPG GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE. The european animal health industry good practice guide to veterinary pharmacovigilance
GVPPG GOOD VETERINARY PHARMACOVIGILANCE PRACTICE GUIDE 2 nd edition, APRIL 2011 The european animal health industry good practice guide to veterinary pharmacovigilance [ 3 ] Foreword This IFAH-Europe
More informationPHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use
PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationConsultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.
Association Européenne des Spécialités Pharmaceutiques Grand Public Association of the European Self-Medication Industry Europäischer Verband der Arzneimittel-Hersteller AESGP Position Paper on the European
More informationGuide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationGxP Inspections within the Centralised Procedure
GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector 2nd EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Focus on Quality Agenda Introduction to work of
More informationUK Standards for Pharmacovigilance Departments 2015
UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires
More informationCSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017
CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection
More informationQSS 0 Products and Services without Bespoke Contracts.
QSS 0 Products and Services without Bespoke Contracts. Use: Typically Sub 50k processes without a bespoke contract. Amendment History Version Date Status V3 June 2018 Updated for 2018 deployment Contents
More informationData Collection Tools Functions, Indicators & Sub-Indicators
Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function
More informationPeriod of time from September 2015 to August Summary of pharmacovigilance system audit report results v3
Report to the European Commission on Pharmacovigilance audits carried out in BASG/AGES (Austrian Federal Office for Safety in Health Care / Austrian Medicines and Medical Devices Agency), Austria Period
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationEU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP
EU Pharmacovigilance Legislation - One Year Later Sarah Daniels; Senior Partner TranScrip Partners LLP Since July 2012 we have officially been operating under EU legislation Directive 2010/84/EU amending
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationReflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples
1 2 3 26 August 2010 EMA/INS/GCP/532137/2010 GCP Inspectors Working Group 4 5 6 Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples Draft Adoption
More informationWork plan for the GMP/GDP Inspectors Working Group for 2018
30 November 2017 EMA/INS/GMP/504401/2017 Inspections, Human Medicines Pharmacovigilance & Committees Division Work plan for the GMP/GDP Inspectors Working Group for 2018 Chairperson: Brendan Cuddy Adopted:
More informationThird Stakeholders forum on the implementation of the new Pharmacovigilance legislation
Safeguarding public health Third Stakeholders forum on the implementation of the new Pharmacovigilance Pharmacovigilance system master file an approach towards system simplification Joanna Harper Inspections,
More informationCMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE
FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version No. : 02 Revision 1 :
More informationCentral Drugs Standard ControlOrganization
Central Drugs Standard ControlOrganization Directorate General of Health Services Ministry of Health and Family Welfare Government of India Risk based programme for pharmaco-vigilance inspections of market
More informationNational self-insurer OHS management system audit tool. Version 3
National self-insurer OHS management system audit tool Version 3 Release Date: 4 August 2014 Next Review Date: 2016 Approval Status: Prepared by: Approved by Heads of Workers Compensation Authorities WorkCover
More informationMASTER VALIDATION PLAN PROCEDURE DRAFT DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE
DRAFT OF A POSSIBLE COMPUTER SYSTEMS VALIDATION MASTER PLAN PROCEDURE 1. PURPOSE The purpose of this SOP is to define the minimum requirements for Computer Systems Validation (CSV) at (insert name of company
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationPharmacovigilance System in India: Industry Perspective
Pharmacovigilance System in India: Industry Perspective Dr. Jamal Baig, Global Pharmacovigilance Country Leader, MSD Pharmaceutical Pvt. Ltd., India. Introduction Currently there are 3 major PV guidelines
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationRegulatory Compliance Inspections at MAH Offices: Implications for Manufacturers
Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers Kevin O Donnell, Ph.D. Market Compliance Manager GMP & Market Compliance Info Day September 2012 Slide 1 What are Regulatory
More informationInternal Auditing and Control of Nonconforming Work
Internal Auditing and Control of Nonconforming Work ISO/IEC 17025, clauses 4.14 and 4.9 www.aphl.org What will be covered in this training? Internal Auditing What is it? Who performs it? What are the possible
More informationINTER-AGENCY JOB MARKET VACANCY NOTICE EMSA/IAJM/AD/2016/02
INTER-AGENCY JOB MARKET VACANCY NOTICE EMSA/IAJM/AD/2016/02 In order to promote the mobility of Temporary Agents across Agencies, the European Maritime Safety Agency (EMSA) wishes to inform Temporary Agents
More informationHANDBOOK OF PUBLIC SECTOR PROCUREMENT PROCEDURES (MAY, 2001)
GOVERNMENT OF JAMAICA HANDBOOK OF PUBLIC SECTOR PROCUREMENT PROCEDURES (MAY, 2001) National Contracts Commission 17 Knutsford Boulevard Kingston 5 Jamaica, West Indies http://www.ocg.gov.jm Acknowledgements
More informationAMF Position Compliance function requirements
AMF Position 2012-17 Compliance function requirements Reference texts: Articles 313-1 to 313-3, 313-5 to 313-7, 313-54, 313-75 of the AMF General Regulation The Autorité des Marchés Financiers applies
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationAudit REPORt. Audit of Offi cial Controls Carried Out at Local Authority Approved Slaughterhouses Galway County Council
Audit REPORt Audit of Offi cial Controls Carried Out at Local Authority Approved Slaughterhouses Audit REPORT Audit of Official Controls Carried Out at Local Authority Approved Slaughterhouses Table of
More informationPharmacovigilance Officer (m/f) Ref. 2011/10/132
Pharmacovigilance Officer (m/f) Ref. 2011/10/132 Our client, a leading European pharmaceutical company is looking to recruit an Pharmacovigilance Officer (m/f) for their Head Office in Luxembourg. Major
More informationModule VIII- Post-authorisation safety studies
Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised
More informationSupervision of manufacturers: What is expected of National Competent Authorities?
Supervision of manufacturers: What is expected of National Competent Authorities? Fergus Sweeney, PhD, European Medicines Agency Head, Compliance and Inspections EU 28: Science, Medicines, Health Dubrovnik,
More informationAnnex II: Evaluation Procedure
Making the railway system work better for society. NSA Monitoring 1 / 22 Procedure Evaluation procedure for the NSA monitoring activity Document Type: Procedure Origin: ERA Document ID: Activity Based
More informationCOMMISSION REGULATION (EU)
17.11.2012 Official Journal of the European Union L 320/3 COMMISSION REGULATION (EU) No 1077/2012 of 16 November 2012 on a common safety method for supervision by national safety authorities after issuing
More informationQ/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008
Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 1. General questions Doc. Ref: CMDh/132/2009/Rev.20 May 2013 Question 1.1 What is the definition of MAH? According
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationSignal Management in the EU and future extended access to EudraVigilance for industry
Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal
More informationPresenter: Ejaz Butt
Presenter: Ejaz Butt Disclaimer The content and opinions expressed in the following PowerPoint slides are those of individuals who prepared the presentation and should not be attributed to Zigzag Associates
More informationNIS Considerations - Bulgaria
NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5
More information1. GLOSSARY EXECUTIVE SUMMARY INTRODUCTION Audit Objective Audit Scope... 5
Audit REPORt Audit of offi cial controls in food business operations catering for high-risk population groups supervised by environmental health offi cers in the Health Service Executive Audit REPORT Audit
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationTABLE OF CONTENTS 1.0 INTRODUCTION...
Advisory Circular Subject: Quality Assurance Programs Issuing Office: Civil Aviation, Standards Document No.: AC QUA-001 File Classification No.: Z 5000-34 Issue No.: 01 RDIMS No.: 9376810-V14 Effective
More informationIndustry perspective: Non-prescription medicines
EMA 7 th Stakeholders forum on the implementation of the new pharmacovigilance legislation 27 September 2013 Industry perspective: Non-prescription medicines Introduction Perfect timing for a review Comprehensive
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationPREPARING A CLIENT FOR INVESTIGATIONS
PREPARING A CLIENT FOR INVESTIGATIONS INVESTIGATIONS Investigations Can Involve: - Industry or Sector Wide Investigation - Targeting a Company or Group of Companies - Unannounced Inspections ( Dawn Raids
More informationCOMMISSION RECOMMENDATION. of XXX. on the audits and assessments performed by notified bodies in the field of medical devices
EUROPEAN COMMISSION Brussels, XXX [ ](2013) XXX draft COMMISSION RECOMMENDATION of XXX on the audits and assessments performed by notified bodies in the field of medical devices (Text with EEA relevance)
More informationWELMEC Application of module D Quality assurance Under directive 2014/32/EU (MID) or directive 2014/31/EU (NAWID)
WELMEC 8.4 2017 Application of module D Quality assurance Under directive 2014/32/EU (MID) or directive 2014/31/EU (NAWID) WELMEC is a cooperation between the legal metrology authorities of the Member
More informationQ&A - Pharmacovigilance Legislation
CMDh/257/2012, Rev.18 July 2017 Regulation (EU) No 1235/2010 and Directive 2010/84/EU Table of contents 1. a. As of 21 July 2012, new requirements for marketing authorisation applications have been introduced
More informationPharmacovigilance System in Russia and the EAEU
Pharmacovigilance System in Russia and the EAEU Authors: Sergey Simeniv CEO X7 Research, CRO; Olga Latysheva Head of Pharmacovigilance Department X7 Research, CRO; Dmitry Kryuchkov Executive Director X7
More informationFunctioning of the PRAC
Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment
More informationUNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS
UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS Executive Summary European Medicines Agency (EMA) regulations for licensing of medical devices include the use of authorized
More informationRecent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility
Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent
More informationCOMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE
COMMON MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION: RULES OF GOOD CLINICAL PRACTICE AND GOOD LABORATORY PRACTICE www.gratanet.com Among other regulations aimed at the implementation of the Agreement
More informationGuideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File
Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...
More informationQUMU CLOUD PLATFORM CUSTOMER SUPPORT AGREEMENT
QUMU CLOUD PLATFORM CUSTOMER SUPPORT AGREEMENT I. DEFINITIONS "Approved Support Contacts" means CUSTOMER employees that are authorized to initiate Support Requests with QUMU Customer Support and that are
More informationWork plan for the GMP/GDP Inspectors Working Group for 2017
13 January 2017 EMA/INS/GMP/584202/2016 Work plan for the GMP/GDP Inspectors Working Group for 2017 Chairperson: David Cockburn Adopted: December 2016 1. Meetings scheduled for 2017 Face-to-face meetings
More information